Institutional growth equity
For proven platforms funding expansion with board-level investor participation.
Healthcare · Equity capital raising
Healthcare equity capital raising
Growth equity and strategic capital for healthcare providers, medical technology, pharma and health-services businesses raising USD 5m or more.
The financing decision
Choose the structure around the operating reality
Healthcare investors need a clear bridge from clinical or service quality to repeatable unit economics, expansion capacity and a defensible route to scale.
We begin with the commercial objective, the amount and timing of capital, the evidence available and the authority to run the transaction. The resulting route can then be tested against realistic investor, lender or buyer criteria.
Typical uses of capital
- New facilities, beds or clinical capacity
- Medical-device commercialisation
- Technology-enabled care expansion
- Regional growth, acquisitions and working capital
Decision information
What counterparties will test
Healthcare evidence
- Patient, procedure or product-level economics
- Clinical outcomes and quality controls
- Payor mix, reimbursement and collection cycles
- Practitioner, channel or distributor concentration
- Expansion capex, ramp-up and governance
Mandate readiness
- Funding requirement of USD 5m or more
- Clear ownership and decision authority
- Historical financial and operating information
- Defined use of funds and transaction timetable
- Management availability for diligence and negotiation
Structuring routes
Structures to evaluate
The route is selected after reviewing cash flows, control, security, dilution, timing and counterparty appetite.
Strategic capital
For businesses benefiting from clinical, distribution or market-access capabilities.
Venture or specialist healthcare capital
For medtech and technology-enabled care with validated milestones and scale evidence.
Execution
How the mandate progresses
- Translate clinical and operating evidence into an investment case
- Build cohort, capacity and expansion economics
- Define valuation and capital structure
- Target healthcare, growth and strategic investors
- Manage diligence, terms and closing workstreams
The sequence is adapted to transaction readiness, confidentiality and the selected capital route.
Relevant live work
Current mandates in this market
Public mandate summaries are current at the website build date. Detailed information is available following counterparty qualification.
USD 50M
Healthcare / pharma platform — growth raise
USD 5M
Multilingual healthcare voice-AI platform — seed capital raise
Questions, answered
Healthcare equity capital raising questions
Provider platforms, pharma, medical devices, diagnostics, digital health and healthcare-services businesses may be considered where the raise is USD 5m or more.
Evidence varies by model and can include clinical outcomes, utilisation, payor mix, unit economics, product validation, distribution and the expansion plan.
Yes. Equity can support organic expansion, acquisitions or a combined buy-and-build plan when targets and funding requirements are credible.
Strategic healthcare, pharma, technology and distribution counterparties can form part of the investor universe where their objectives fit the transaction.
Discuss a healthcare equity capital raising mandate
Share your company, transaction type and approximate ticket size. A partner will review the fit for a USD 5m+ mandate.
